Welcome to the Leuven Cancer Institute

The Leuven Cancer Institute was established as part of KU Leuven and University Hospitals Leuven. At LKI basic scientists, clinical researchers and doctors join forces. Their aim is to fight cancer even more effectively and to offer the best chances to patients with cancer. LKI strives for a leading position in care, diagnosis, therapy, research and training. LKI is also dedicated to meeting patients’ social and emotional needs.

You can rely on our commitment. With your help we hope to boost our efforts: every new ally makes us stronger in our battle against cancer. We sincerely thank you for your trust and support.

PI3K/mTOR inhibitors may be effective against some uterine sarcomas
published on 24 february 2017

The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may respond to PI3K/mTOR inhibitors, according to a study by Frédéric Amant.



Tik een trefwoord in,
onze zoekmachine laat u toe om zeer gedetailleerd te zoeken.

Support our progress

 

Every patient is unique. In fact, every tumour is unique. Therefore, to make sure our patients receive the optimal care they need, we are developing ‘personalized therapies’. However, developing and implementing new therapies is hugely expensive. Your support is literally our lifeline.

 

LKI in facts and figures - 2015
icon
23884
chemotherapy sessions
icon
33892
oncological patients
icon
891
scientific publications
icon
42487
radiotherapy sessions

 

Along with LKI’s Friends and Ambassadors,
we build a network of engaged donors who support our research and cancer care in a special way.
You can also participate.

Read more